# Leprosy for NEET PG Dermatology: Cardinal Signs, NLEP 2025 PB/MB Classification and 3-Drug MDT, Spectrum, Reactions and ENL, SDR-PEP

Source: https://tracknation.in/story/leprosy-for-neet-pg-dermatology-cardinal-signs-nlep-2025-pb-mb-classification-and-3-drug-mdt-spectrum-reactions-and-enl-sdr-pep (TrackNation — free UPSC notes with PYQs)

> NEET PG Dermatology: leprosy transmission and incubation, the WHO cardinal signs, India's 2025 PB/MB classification and three-drug regimen, the tuberculoid–lepromatous spectrum, nerve damage and deformity, type 1 and type 2 reactions, and NLEP prevention and goals, with a diagram, hooks, vignette MCQs and cards.

## Start Here

🎯 **Exam priority: High (Dermatology and PSM).** *Expect: the three cardinal signs, PB vs MB under the 2025 Indian rules, the
three-drug regimen now used for PB too, doses and durations, tuberculoid vs lepromatous features, ulnar claw hand and foot drop, type 1 vs type 2
reactions and their drugs, SDR-PEP for contacts, Grade 2 disability as an indicator, and NLEP milestones.*

CBME mapping: **DR 9.1–9.6**. Programme details are also in PSM; *M. leprae* in Microbiology.

*NLEP 2025 PB and MB classification and regimen; WHO cardinal signs; leprosy spectrum; reactions and programme. Drawn by TrackNation.*

## The Disease and Its Diagnosis

- Chronic infection by the acid-fast *Mycobacterium leprae* (and *M. lepromatosis*) with a tropism for **skin, peripheral
nerves**, upper respiratory mucosa and eyes. Spread by **droplets from the nose and mouth** of untreated patients during prolonged close
contact — not by casual contact; only untreated lepromatous disease is meaningfully contagious. Incubation: a few months to 20 years. Armadillos are a
zoonotic source in the Americas.

- **WHO cardinal signs** (any one is diagnostic): (1) definite loss of sensation in a pale or reddish skin patch; (2) a thickened
peripheral nerve with sensory loss or weakness of the muscles it supplies; (3) bacilli on a **slit-skin smear**.

- **Spectrum**: tuberculoid — one or a few anaesthetic, hypopigmented macules with sharp raised borders and enlarged nerves (good
cell-mediated immunity); lepromatous — widespread symmetric nodules and thickening, loss of eyebrows and eyelashes, gynaecomastia, nose, testis and
kidney involvement (poor cell-mediated immunity); borderline — unstable, shifting towards either pole. Biopsy the advancing edge in tuberculoid and a
nodule in lepromatous disease; PCR helps in early or atypical cases.

- Nerve damage: ulnar → **claw 4th and 5th fingers**; common peroneal → **foot drop**; corneal insensitivity and iritis →
scarring and blindness. Lepromatous disease may cause amyloidosis and infertility.

## Classification and Treatment (NLEP 2025)

- **PB**: 1–5 skin lesions, no nerve involvement, smear negative. **MB**: more than 5 lesions, or one or more nerves
involved (including pure neuritis), or a positive smear.

- From **1 April 2025** India uses the **same 3-drug MDT (rifampicin, clofazimine, dapsone) for PB and MB**, replacing the
old 2-drug PB regimen: **6 months for PB, 12 months for MB**. Patients already on treatment on 31 March 2025 finish their old regimen.
Monthly doses are supervised; daily doses are self-administered. MDT is free in all public facilities.

| **NLEP regimen (from 1 April 2025)**

 | **Rifampicin**

 | **Clofazimine**

 | **Dapsone**

 | **Duration**

 |
| Adult PB

 | 600 mg monthly

 | 300 mg monthly + 50 mg daily

 | 100 mg daily

 | 6 months

 |
| Adult MB

 | 600 mg monthly

 | 300 mg monthly + 50 mg daily

 | 100 mg daily

 | 12 months

 |
| Child 10–14 y

 | 450 mg monthly

 | 150 mg monthly + 50 mg alternate days

 | 50 mg daily

 | PB 6 / MB 12 months

 |
| Child (younger)

 | 10 mg/kg monthly

 | 100 mg monthly + 50 mg twice weekly

 | 2 mg/kg daily

 | PB 6 / MB 12 months

 |

## Reactions, Disability and the Programme

- **Type 1 (reversal) reaction**: a spontaneous rise in cell-mediated immunity — inflamed existing lesions and neuritis — treated with
prednisone 40–60 mg/day tapered to a low maintenance dose over months; cyclosporine if steroids fail.

- **Type 2 reaction — erythema nodosum leprosum (ENL)**: immune-complex vasculitis/panniculitis with crops of painful red nodules,
fever, neuritis, lymphadenitis, orchitis, arthritis and glomerulonephritis; less common since clofazimine joined MDT. Mild — aspirin; significant —
a week of prednisone; recurrent or severe — **thalidomide** (never in women who may become pregnant).

- **Prevention**: contact screening with **single-dose rifampicin post-exposure prophylaxis (SDR-PEP)** for eligible
contacts. **DPMR**: self-care training, dressings, **micro-cellular rubber (MCR) footwear**, reconstructive surgery at district
hospitals or medical colleges with a welfare allowance.

- **NLEP**: began as NLCP in 1955 (dapsone monotherapy); MDT era from the 1980s; leprosy made **notifiable in 2025**;
National Strategic Plan 2023–27 aims to **interrupt transmission at district level by 2027** — zero transmission, disability and
discrimination. **Grade 2 disability** in new cases is the key indicator of late diagnosis.

## Traps the Examiner Sets

- Since April 2025, PB patients in India also get clofazimine — three drugs for 6 months.

- Any nerve involvement makes a case MB.

- Type 1 = cell-mediated (reversal); type 2 = immune complex (ENL) → thalidomide if recurrent.

- Grade 2 disability among new cases signals delayed detection.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **Cardinal signs 'Patch, Nerve, Smear' — any one** — diagnosis

- 🧠 **'Five or fewer and nerve-free = PB'** — classification

- 🧠 **MDT 'R-C monthly, D-C daily; 6 for PB, 12 for MB'** — regimen

- 🧠 **Reactions: 'Type 1 = Turn-around immunity; Type 2 = Two (immune complexes), thalidomide'** — reactions

- 🧠 **'Ulnar claws, Peroneal drops'** — nerve deformities

## Rapid-Revision Cards

- M. leprae (± M. lepromatosis); skin and nerves.

- Nasal/oral droplets, prolonged contact.

- Months to 20 years.

- Anaesthetic patch; thick nerve; smear +.

- 1–5 lesions, no nerve, smear −.

- > 5 lesions or any nerve or smear +.

- R + C + D for both PB and MB.

- PB 6 months; MB 12 months.

- R 600 + C 300 (supervised).

- D 100 + C 50.

- R 450, C 150 monthly; D 50 daily.

- Few, sharp, anaesthetic; good CMI.

- Many nodules, madarosis, gynaecomastia.

- Claw 4th–5th fingers.

- Foot drop.

- Rising CMI → prednisone.

- Painful nodules, orchitis → thalidomide.

- Single-dose rifampicin for contacts.

- 2025.

- District-level interruption by 2027.

- Indicator of late diagnosis.

## Sources

*Facts in this article were checked against these documents.*

- National Leprosy Eradication Programme (NLEP) — Directorate General of Health Services, MoHFW, 2025 (link)

- Revised treatment regimen for PB and MB cases in India (D.O. letter, 6 March 2025) — Directorate General of Health Services, MoHFW, 2025

- Leprosy fact sheet — World Health Organization, January 2026 (link)

- MSD Manual Professional: Leprosy (Hansen Disease) — Merck & Co. (MSD Manuals), reviewed 2026 (link)

- Competency Based Undergraduate Curriculum, Dermatology (DR 9) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** Leprosy is mainly transmitted by

- (a) mosquitoes

- (b) droplets from the nose and mouth of untreated patients during close contact

- (c) shaking hands

- (d) contaminated water

**Answer: (b)** — Not by casual contact.

**Q2.** The incubation period of leprosy ranges from

- (a) a few months to 20 years

- (b) 1–3 days

- (c) exactly 6 months

- (d) 1–2 weeks

**Answer: (a)** — Very long.

**Q3.** Which is a WHO cardinal sign of leprosy?

- (a) silvery scales

- (b) definite loss of sensation in a pale or reddish skin patch

- (c) fever with rash

- (d) itchy annular plaque

**Answer: (b)** — Any one of three signs is enough.

**Q4.** The other two cardinal signs are

- (a) anaemia and splenomegaly

- (b) fever and weight loss

- (c) a thickened nerve with sensory loss or weakness, and bacilli on slit-skin smear

- (d) lymphadenopathy and cough

**Answer: (c)** — WHO.

**Q5.** Under the 2025 Indian classification, a patient with 3 anaesthetic patches, no nerve involvement and a negative smear is

- (a) multibacillary

- (b) paucibacillary

- (c) indeterminate, no treatment

- (d) pure neuritic

**Answer: (b)** — 1–5 lesions, no nerve, smear negative.

**Q6.** A patient with 2 skin patches and one thickened ulnar nerve is classified as

- (a) tuberculoid, no treatment

- (b) multibacillary

- (c) paucibacillary

- (d) pure neuritic PB

**Answer: (b)** — Any nerve involvement → MB.

**Q7.** From 1 April 2025, paucibacillary leprosy in India is treated with

- (a) rifampicin and dapsone for 6 months

- (b) dapsone alone for 2 years

- (c) rifampicin, clofazimine and dapsone for 6 months

- (d) the same drugs for 12 months

**Answer: (c)** — 3-drug regimen replaces the 2-drug PB regimen.

**Q8.** The duration of MDT for adult multibacillary leprosy is

- (a) 3 months

- (b) 24 months

- (c) 12 months

- (d) 6 months

**Answer: (c)** — PB 6 months.

**Q9.** The supervised monthly doses in adult MDT are

- (a) rifampicin 450 mg only

- (b) isoniazid 300 mg

- (c) rifampicin 600 mg and clofazimine 300 mg

- (d) dapsone 100 mg and clofazimine 50 mg

**Answer: (c)** — Daily: dapsone 100 + clofazimine 50.

**Q10.** The adult daily self-administered doses in MDT are

- (a) rifampicin 600 mg daily

- (b) clofazimine 300 mg daily

- (c) dapsone 100 mg and clofazimine 50 mg

- (d) dapsone 50 mg alternate days

**Answer: (c)** — Per NLEP table.

**Q11.** A 12-year-old with MB leprosy receives monthly rifampicin of

- (a) 150 mg

- (b) 600 mg

- (c) 450 mg

- (d) 10 mg/kg weekly

**Answer: (c)** — Child 10–14: rifampicin 450, clofazimine 150 monthly.

**Q12.** A patient has one hypopigmented, numb macule with a sharp raised border and an enlarged nerve nearby; immunity to M. leprae is strong. The pole of the spectrum is

- (a) lepromatous

- (b) borderline lepromatous

- (c) histoid

- (d) tuberculoid

**Answer: (d)** — Few lesions, good CMI.

**Q13.** Widespread symmetric nodules, loss of eyebrows and gynaecomastia indicate

- (a) type 1 reaction

- (b) lepromatous leprosy with poor cell-mediated immunity

- (c) indeterminate leprosy

- (d) tuberculoid leprosy

**Answer: (b)** — Lepromatous pole.

**Q14.** Clawing of the ring and little fingers in leprosy results from involvement of the

- (a) ulnar nerve

- (b) median nerve

- (c) radial nerve

- (d) common peroneal nerve

**Answer: (a)** — Peroneal → foot drop.

**Q15.** Foot drop in leprosy is due to damage of the

- (a) sciatic nerve trunk

- (b) femoral nerve

- (c) common peroneal nerve

- (d) tibial nerve

**Answer: (c)** — Lateral popliteal.

**Q16.** Blindness in leprosy can follow

- (a) retinal detachment only

- (b) cataract from MDT

- (c) optic neuritis only

- (d) corneal insensitivity with scarring, or iritis

**Answer: (d)** — Eye care is part of DPMR.

**Q17.** For skin biopsy in tuberculoid leprosy, the sample is taken from the

- (a) centre of the lesion

- (b) advancing edge of the lesion

- (c) earlobe only

- (d) normal skin

**Answer: (b)** — Nodules or plaques in lepromatous.

**Q18.** Existing leprosy patches suddenly become red and swollen with painful nerves during treatment. This type 1 reaction is due to

- (a) secondary infection

- (b) immune complex deposition

- (c) a spontaneous rise in cell-mediated immunity

- (d) drug allergy to dapsone

**Answer: (c)** — Reversal reaction.

**Q19.** The treatment of a significant type 1 reaction is

- (a) prednisone 40–60 mg/day, tapered to a low maintenance dose

- (b) thalidomide

- (c) antibiotics only

- (d) stop MDT

**Answer: (a)** — Cyclosporine second line.

**Q20.** A patient with lepromatous leprosy develops crops of painful red nodules with fever, neuritis and orchitis. The diagnosis is

- (a) dapsone syndrome

- (b) relapse

- (c) type 1 reaction

- (d) erythema nodosum leprosum (type 2 reaction)

**Answer: (d)** — Immune-complex mediated.

**Q21.** The drug of choice for recurrent or severe ENL is

- (a) isoniazid

- (b) thalidomide

- (c) dapsone

- (d) rifampicin

**Answer: (b)** — Not in women who may become pregnant.

**Q22.** ENL has become less common since the addition to MDT of

- (a) dapsone

- (b) rifampicin

- (c) clofazimine

- (d) ofloxacin

**Answer: (c)** — Clofazimine is anti-inflammatory as well.

**Q23.** Household contacts of a new leprosy case are offered

- (a) single-dose rifampicin post-exposure prophylaxis after screening

- (b) dapsone for 2 years

- (c) nothing

- (d) BCG revaccination only

**Answer: (a)** — SDR-PEP.

**Q24.** Under DPMR, patients with insensitive feet are given

- (a) steroid injections

- (b) only analgesics

- (c) micro-cellular rubber (MCR) footwear and self-care training

- (d) amputation

**Answer: (c)** — Disability prevention.

**Q25.** Leprosy was declared a notifiable disease in India in

- (a) 2016

- (b) 2005

- (c) 1955

- (d) 2025

**Answer: (d)** — NLEP timeline.

**Q26.** The National Strategic Plan for leprosy aims to interrupt transmission at district level by

- (a) 2047

- (b) 2035

- (c) 2027

- (d) 2030

**Answer: (c)** — WHO Global Leprosy Strategy runs to 2030.

**Q27.** Which NLEP indicator best reflects delayed diagnosis?

- (a) Grade 2 disability among new cases

- (b) number of MDT blister packs

- (c) child sex ratio

- (d) prevalence rate

**Answer: (a)** — Visible deformity at diagnosis.

**Q28.** India's leprosy control programme began in 1955 using

- (a) rifampicin alone

- (b) MDT

- (c) BCG

- (d) dapsone monotherapy

**Answer: (d)** — MDT came in the 1980s.

**Q29.** A patient treated for leprosy needs reconstructive surgery for a claw hand. Under NLEP this is done at

- (a) district hospitals, medical colleges or leprosy institutes, with a welfare allowance

- (b) it is not offered

- (c) private clinics only

- (d) PHC only

**Answer: (a)** — Rs 12,000 allowance.

**Q30.** Which form of leprosy is contagious?

- (a) patients on MDT

- (b) tuberculoid on treatment

- (c) all forms, highly

- (d) only untreated lepromatous (multibacillary) disease, and not easily

**Answer: (d)** — Patients become non-infectious quickly on MDT.

### Active Recall

From memory: give the cardinal signs, the 2025 PB/MB definitions and the adult MDT regimen with durations, contrast tuberculoid and lepromatous leprosy, describe the nerve deformities, explain type 1 and type 2 reactions with treatment, and list NLEP prevention measures and goals.
